<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-75545</identifier>
<setSpec>1130-1406</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Opportunistic co-infection in a patient with Crohn's disease during infliximab (anti-TNF-alpha) therapy</dc:title>
<dc:description xml:lang="en">Background The biological therapies for chronic inflammatory diseases of autoimmune origin, particularly drugs inhibiting cytokines, such as the antagonists of the tumoral necrosis factor alpha (TNFalpha), are acceptably well tolerated in patients suffering rheumatologic, dermatologic and gastrointestinal pathologies. Nevertheless, pharmacologic vigilance studies have clarified several aspects of their security in daily clinical use. The adverse effects associated with inhibitors of TNFalpha can be related to the target (or class) and to the agent. The adverse effects related to the target include those potentially attributable to the inherent immunosuppressive state due to the blockade of the main cytokine, phenomenon that could increase the susceptibility to the infections and cancer. Aims To expound the potential risk of serious infections, opportunistic or not, inherent to the use of biological therapies and, specifically, antagonistic drugs of TNFalpha, from the description of a case of invasive fungal infection. Methods Revision of clinical records, obtained from the chronic inflammatory disease of autoimmune origin patient database, candidates or recipients of the new biological therapies, and study of the microbiological isolates. Conclusions Invasive fungal infections, with isolated or associated clinical presentation to other opportunistic infections, are emerging in new groups-at-risk as they are the recipients of anti-cytokine biological therapies, regulators of inflammation and immunity. They can be potentially serious in their evolution and a high index of suspicion is needed sometimes for their prompt diagnosis. Possible preventive measures in patients with a high risk of suffering them will have to be investigated(AU)</dc:description>
<dc:creator>Nos, Pilar</dc:creator>
<dc:creator>Pemón, Javier</dc:creator>
<dc:creator>Salavert, Miguel</dc:creator>
<dc:creator>Bastida, Guillermo</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivos Exponer y concienciar acerca del riesgo potencial de causar infecciones graves, oportunistas o no, inherentes al empleo de tratamientos biológicos y, en concreto, de fármacos bloqueadores del TNF-alfa, a partir de la descripción de un caso de infección fúngica invasiva. Métodos Revisión de la historia clínica a partir de la selección del caso obtenido en la base de datos de pacientes con enfermedades inflamatorias crónicas de base autoinmune, candidatos o a los que se les realizan nuevos tratamientos biológicos, y estudio de los aislamientos microbiológicos procedentes de las muestras clínicas significativas. Resultados Se comunica un caso de infección oportunista dual (nocardiosis y aspergilosis) de difícil diagnóstico y complejo tratamiento en un paciente afectado de enfermedad de Crohn e inmunodeprimido, que se desencadenó tras la administración de infliximab (anticuerpo monoclonal anti-TNF-alfa). Conclusiones Las infecciones fúngicas invasivas, bien con presentación clínica aislada o asociadas a otras infecciones oportunistas, están emergiendo en nuevos grupos de riesgo, como son los pacientes receptores de tratamientos biológicos anticitocinas reguladoras de la inflamación y de la inmunidad. Pueden ser potencialmente graves y se precisa un alto índice de sospecha para su diagnóstico precoz. En los pacientes con mayor riesgo de presentarlas deben investigarse las posibles medidas preventivas para evitar su aparición o minimizar su trascendencia(AU)</dc:description>
<dc:source>Rev Iberoam Micol;26(3): 213-217, sept. 2009. ilus</dc:source>
<dc:identifier>ibc-75545</dc:identifier>
<dc:title xml:lang="es">Coinfección oportunista durante el tratamiento con infliximab (antifactor de necrosis tumoral alfa) en un paciente con enfermedad de Crohn</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d23973^s22012</dc:subject>
<dc:subject>^d920^s22020</dc:subject>
<dc:subject>^d29591^s22006</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d9802^s22001</dc:subject>
<dc:subject>^d9804^s22036</dc:subject>
<dc:subject>^d9802^s22052</dc:subject>
<dc:subject>^d1716^s22020</dc:subject>
<dc:subject>^d24572</dc:subject>
<dc:type>article</dc:type>
<dc:date>200909</dc:date>
</metadata>
</record>
</ibecs-document>
